T
Thomas Brunner
Researcher at University of Konstanz
Publications - 511
Citations - 26076
Thomas Brunner is an academic researcher from University of Konstanz. The author has contributed to research in topics: Apoptosis & Medicine. The author has an hindex of 75, co-authored 448 publications receiving 23438 citations. Previous affiliations of Thomas Brunner include University Medical Center Freiburg & University of Oxford.
Papers
More filters
Journal ArticleDOI
Comparative analysis between interstitial brachytherapy and stereotactic body irradiation for local ablation in liver malignancies.
Peter Hass,Konrad Mohnike,Siegfried Kropf,Thomas Brunner,Mathias Walke,D. Albers,Cordula Petersen,Robert Damm,Franziska Walter,Jens Ricke,Maciej Powerski,Stefanie Corradini +11 more
TL;DR: The planning study showed a superior outcome of BT regarding dose coverage of the target volume and exposed liver volume and further studies are needed to determine ideal applicability for each treatment approach.
Journal ArticleDOI
Simultaneous Online Determination of S, Cl, K, Na, Zn, and Pb Release from a Single Particle during Biomass Combustion. Part 1: Experimental Setup–Implementation and Evaluation
TL;DR: In this article, a single-particle reactor was designed, which has been coupled to an inductively coupled plasma mass spectrometer (ICP-MS) for targeted experiments in a temperature range of 250-1050 °C under inert, reducing, and oxidizing conditions.
Journal ArticleDOI
Synergistic induction of the Fas (CD95) ligand promoter by Max and NFκB in human non-small lung cancer cells
Zoltan Wiener,Edgar Ontsouka,Sabine Jakob,Ralph Torgler,A. Falus,Christoph Mueller,Thomas Brunner +6 more
TL;DR: It is concluded that high levels of Max and stress-induced NFkappaB activation may result in elevated expression of Fas ligand in human lung cancer cells and possibly contribute to Fas ligands-associated immune escape mechanisms.
Proceedings ArticleDOI
LoRa vs. LoRa: In-Field Evaluation and Comparison For Long-Lifetime Sensor Nodes
TL;DR: A smart sensor node for the long term and long-range monitoring that use the novel transceiver to transmit data to a remote gateway that shows the improvements of the new SX126x transceiver with up to 72% of power saved in transmission over the same conditions.
Journal ArticleDOI
Esophageal cancer. A prospective phase II study of concomitant-boost external-beam chemoradiation with a top-up endoluminal boost.
TL;DR: Survival was excellent especially for patients without nodal disease in this dose-intensified schedule with acceptable tolerability, and the median overall survival was significantly longer than previously reported.